Although herpes simplex virus type-1 (HSV-1) can be used as an oncolytic virus it has the undesirable side effect of neurotoxicity. To create a virus with improved specificity for oral cancer we used a fragment of human papillomavirus type-16, which is frequently found in oral and cervical cancers, but not elsewhere. The upstream regulatory region, URR16, was shown to have a high level of transcriptional activity in three of four oral cancer cell lines but low activity in three cell lines derived from brain cancers. URR16 was therefore placed in HSV-1, replacing the promoter of the essential gene ICP4, and the resulting virus was named HSPV-1. When cells were infected with HSPV-1, ICP4 was expressed at levels that were not associated with the level of activity of URR16. The virus replicated in each type of cell to a final titer that showed a correlation with the level of expression of ICP4, but with no correlation to either the tumor of origin or the presence of HPV sequences in the cells. To find if some function of HSV-1 was affecting the activity of URR16, oral cancer cells were transfected with a URR-reporter construct and were then infected with virus. This induced transcription, which was attributed to immediate-early viral genes other than ICP4. A promoter/enhancer from a papillomavirus therefore has the potential to regulate the functions of an oncolytic strain of HSV-1, and is affected by functions of both the host cell and of HSV-1 itself.
Introduction
Head and neck squamous cell carcinoma (HNSCC) affects nearly 30 000 people in the US each year. If diagnosed in the early stages the 5-year survival rates are between 60 and 90%, but more commonly the disease is advanced leading to a 5-year survival rate of below 50%. Even though many advances in therapy have been realized, the 5-year survival rate for HNSCC has improved by only 5% over the last 30 years. 1 Major risk factors of HNSCC are alcohol and tobacco exposure, but human papillomaviruses (HPV) are found in significantly more oral cancers than in corresponding normal oral tissues, 2 with HPV-16 being present in some 20% of these tumors. 3 Some groups have begun to develop oncolytic viral therapy in the hopes of improving the outcome in a variety of cancers. For oral cancer, a prime candidate virus is herpes simplex virus type-1 (HSV-1) which has several relevant features. First, the site of naturally occurring infections by HSV-1 is generally the oral epithelium which is also the tissue of origin of most oral cancers. 4 Thus the virus is very capable of infecting and killing oral cancer cells. 5 Second, the functions of most of the genes of HSV-1 have been identified, which allows them to be manipulated for specific purposes. Third, the availability of antiherpetic drugs such as ganciclovir or acyclovir provides safety in controlling the virus.
Several strategies have been used to generate oncolytic herpes viruses. One has consisted of the deletion of selected genes, as for example in strain G207. To prevent viral replication in neural cells, both copies of the g-1 34.5 gene, which is believed to play a role in neurovirulence, were deleted.
6 G207 was also made selective for replicating cells by inactivation of the gene for ribonucleotide reductase. This virus has been used in early phase clinical trials for glioma, but due to its attenuated growth provided little benefit in clinical outcome. 7 Although it was designed for treatment of gliomas, G207 has since been suggested for use in oral cancer as well as other cancers. [8] [9] [10] Another strategy for control of replication of HSV-1 is the use of specific promoters to regulate the expression of essential genes. The first example was G92A, a recombinant HSV-1 that expresses the essential immediate early gene ICP4 under control of the albumin enhancer/ promoter. 11 This virus was shown to grow only in albumin-expressing hepatoma and hepatocellular carcinoma cell lines. Other examples of promoter-driven specificity in HSV-1 are the B-myb promoter, 12 the DF3/MUC-1 promoter, 13 the calponin promoter 14 and a b-catenin-dependent promoter. 15 A source of promoters that has received little attention to date is the human papillomavirus family of viruses (HPVs). These viruses are restricted to epithelial tissues and tumors largely by the tissue-specificity of the Upstream Regulatory Region (URR) of their genomes. 16, 17 In previous studies, we found that the URR of HPV-16 (URR16) provided a very specific level of expression of a reporter gene in oral cancer cells, when compared with other promoters. 18 We have therefore attempted to place the essential immediate-early gene of HSV, ICP4, under transcriptional control of URR16 in an effort to create an oncolytic herpes virus with specificity for oral cancer.
Materials and methods

Cells
The oral cancer cell line, Tu167, was kindly provided by Dr G Clayman (MD Anderson Cancer Center, Houston, TX). 686LN and 1483 cells were a generous gift of Dr P Sacks (Memorial Sloan Kettering Cancer Center, New York, NY). The oral cancer cells SCC25, and the brain cancer cell lines U373, U87 and IMR32 along with Vero cells were obtained from the American Type Culture Collection (Manassas, VA). The ICP4-complementing cell line n33 was a gift of Dr PA Schaffer (Harvard Medical School, Boston, MA). Tu167, U87, IMR32, Vero and n33 cells were grown in Dulbecco's modified Eagle's medium (DMEM). SCC25 cells were grown in RPMI-1640 medium. 686, 1483 and U373 cells were grown in DMEM F-12 medium. All media contained 10% fetal bovine serum.
To determine which cell lines contained DNA of HPV they were tested for the presence of DNA of HPV-16 and HPV-18 by PCR, followed by DNA sequencing of amplified bands, as before. 19 
Viruses
The virus d120, an ICP4-null mutant of HSV-1, was a gift of Dr PA Schaffer. KOS, the parental strain of d120, and HSPV-1 viruses were propagated in Vero cells while d120 was propagated in n33 cells. All infections were carried out in serum-free medium allowing 1 h for viral absorption. To inactivate the KOS virus by UV light it was exposed to 700 mW cm À2 for 1 min on ice (UV-KOS). To inactivate virus by formaldehyde it was mixed with 2% formalin, and excess formaldehyde was neutralized by 10% sodium bisulfite (FIX-KOS). The titers of UV-KOS and FIX-KOS were measured to ensure that they were less than 10 plaque-forming units (PFU) ml
À1
.
Promoter activity
Cells were plated in 6-well plates at 2 Â 10 5 cells/well. To measure the activity of the HPV-16 URR, cells were transfected with a mixture of plasmids HPV16pGL2 18 and CMV-b-gal (Clontech, Mountain View, CA), using Effectene Transfection Reagent (Qiagen, Valencia, CA) according to the manufacturer's protocol. Two days later, the cells were lysed and the expression level of luciferase was measured using a Luciferase Assay System (Promega, Madison, WI), and was corrected for efficiency of transfection against the expression of b-galactosidase in the same culture. Results were expressed relative to the expression from cells that were transfected with a plasmid in which the luciferase gene was adjacent to no promoter. To measure induction of URR16 by HSV, cells were transfected for 24 h and then infected with 1.0 PFU cell À1 of virus. Luciferase expression was measured 18 h later.
PCR PCR amplification of HSV sequences was done using the GC RICH PCR System (Roche, Mannheim, Germany). All non-HSV sequences were amplified using Taq DNA polymerase (Promega, Madison, WI). Primers were designed using published sequences for HSV-1 (GenBank: X14112) and HPV-16 (GenBank: K02718) ( Table 1) . PCR reactions were run with molecular weight standards on 0.8% agarose gels containing ethidium bromide and visualized by UV light.
Construction of HSPV-1
The plasmid pn11, containing the ICP4 gene of HSV-1 with its native promoter, was generously provided by Dr PA Schaffer. The promoter was removed by digestion with HindIII and SalI. A linker was then inserted containing four restriction sites-SalI-XhoI-KpnIHindIII-to generate pn11-SXKH. URR16 was removed from plasmid HPV16pGL2 by digestion with KpnI and SalI and was inserted into pn11-SXKH resulting in pn11-URR-ICP4. The right intergenic region of HSV-1 between US9 and US10 (RIGR) was amplified directly from strain KOS using primers RIGR-BspUL11I 5 0 and RIGR-BspUL11I 3 0 , which also inserted restriction sites for BspLU11I (Table 1) , and was inserted resulting in pn11-URR-ICP4-RIGR. The left intergenic region (LIGR) was similarly amplified from KOS and was inserted into the HindIII-digested pn11-URR-ICP4-RIGR plasmid to generate the plasmid pHSPV-1. The structure of this plasmid was confirmed by sequencing across each junction in both directions.
To generate recombinant virus, Vero cells were transfected with pHSPV-1 by Effectene. After 48 h, the transfected cells were infected with HSV strain d120. Twenty-four hours later the cells were harvested, then frozen and thawed to release viral particles. From this lysate 24 plaques were obtained and were screened by PCR for presence of the URR. Two were found to be positive. One of them was plaque-purified three times and then propagated in Vero cells resulting in a mutant virus which was named HSPV-1.
Southern blotting Viral DNA was obtained using DNAzol (Invitrogen, Carlsbad, CA) 2 days after infection of Vero cell monolayers with 0.1 PFU cell
À1
. To control for the Oncolytic herpes/papillomavirus mutant C Griffith et al presence of cellular DNA, Vero and n33 DNA was harvested at the same time. HindIII-digested DNA was separated on a 1% agarose gel overnight at 4 1C and transferred onto a positively charged nylon membrane (Ambion, Austin, TX) by capillary transfer. Membranes were hybridized with DIG-labeled probes derived from the RIGR, ICP4 and URR16 using the DIG high prime labeling kit as per the manufacturer's protocol (Roche, Mannheim, Germany). Probed membranes were exposed to X-ray film overnight.
Expression levels of ICP4
Cells were plated in 6-well plates for 24 h prior to infection at 5 PFU cell
À1
. At appropriate times postinfection, lysates were harvested. Proteins were separated on a 10% SDS-PAGE gel and transferred by electrophoresis onto PVDF. ICP4 was detected by staining with the monoclonal antibody RGI 1101 (Rumbaugh-Goodwin Institute, Plantation, FL) followed by washing and incubation with alkaline phosphatase-conjugated antimouse antibody. Membranes were then reacted with the substrate, Lumi-Phos (Pierce, Southfield, MI), and exposed to X-ray film. Analysis by densitometry was performed using Quantity One software (Bio-Rad, Hercules, CA). Some lanes in each gel were loaded with serial dilutions of extracts of Tu167 cells that had been infected with KOS for 4 h, and these were used to calibrate the expression levels in other cells. . At indicated times, cell growth was assayed by conversion of Thiazolyl blue into formazan as before 20 and measurement of (OD 560 ÀOD 690 ) with a spectrophotometer. 
Viral replication
Results
Presence of HPV in cell lines
Nucleotide coordinates refer to the position of the first nucleotide of the primer in the complete genome of HSV-1 (GenBank: X14112) or HPV-16 (GenBank: K02718). Italics indicate restriction enzyme recognition sites, which were created in some cases by changes to the published sequence as shown underlined. Primers were used in pairs as follows: RIGR- Oncolytic herpes/papillomavirus mutant C Griffith et al
Structure of HSPV-1
The structure of HSPV-1 was confirmed by PCR, DNA sequencing and Southern blot analysis. PCR primers were designed using published sequences of HSV-1 and HPV-16, such that a unique pattern of amplification bands would indicate insertion of the URR16-ICP4 construct between US9 and US10 of the genome of d120 (Figure 3) . Amplification of the RIGR confirmed its presence in d120, pHSPV-1 and HSPV-1. Amplification of URR16 from HSPV-1 confirmed its presence in the virus. Amplification from the LIGR to the RIGR in strain d120 showed the predicted band of 1149 base pairs (bp). The same primer pairs failed to amplify a band from HSPV-1, consistent with their binding sites having been separated by a construct that was larger than the amplifiable size. Amplification from URR16 to ICP4 generated a band of around 353 bp in both HSPV-1 and pHSPV-1, which was confirmed by DNA sequencing to represent the junction between URR16 and the ICP4 gene. A PCR that paired a primer upstream of the LIGR with one in URR16 produced a band of around 1986 bp in HSPV-1, indicating insertion of the URR just downstream of the LIGR. This band was not seen in d120. In pHSPV-1 no amplification of this band occurred, consistent with the lack of upstream sequences in the plasmid (Figure 4 ). Southern blotting of viral DNA that had been digested with HindIII showed that neither the ICP4 nor URR probes hybridized to DNA from d120, although the RIGR probe did. Each probe hybridized to DNA from HSPV-1, consistent with URR16 and ICP4 being in the same HindIII fragments of the viral genome (not shown).
Expression of ICP4 in infected cells
Immunoblots of lysates of n33 cells that had been infected with HSPV-1 showed expression of ICP4 ( Figure 5 ). In addition, a smaller band of 34 kDa was seen in cells infected with d120 or HSPV-1, consistent with the truncated, nonfunctional fragment of the gene that remains in d120. As expected, the monoclonal anti-ICP4 RIGR  URR16  URR16-ICP4  HSV-URR16   RIGR  URR16 URR16-ICP4 Figure 3 The genomic structure of HSPV-1. KOS: The prototypical arrangement of the genome of HSV-1, strain KOS. d120: The mutant from which both copies of the gene for ICP4 are largely deleted. The intergenic region between US9 and US10, which is the same in KOS and d120, is shown enlarged. HSPV-1: The structure of the mutant that was constructed by insertion of the URR from HPV-16 together with the gene for ICP4 into the intergenic region of d120. pHSPV-1: The essential region of the plasmid that was constructed in order to combine URR16 and the gene for ICP4 into d120. Solid bars indicate the regions that were amplified by PCR, using the primers of Table 1 , for confirmation of the structure. Oncolytic herpes/papillomavirus mutant C Griffith et al antibody did not stain the ICP4 that is expressed constitutively by n33 cells, which is from HSV-2. Quantitative immunoblots to measure the level of expression of ICP4 were done on lysates of KOS-infected and HSPV-1-infected cells at different times post-infection. These blots showed expression of ICP4 by both KOS and HSPV-1 in each cell line (Figure 6 ). At 4 h postinfection the levels of ICP4 in HSPV-1-infected cells were highest in the HPV-negative oral cancer cell lines Tul67 and SCC25 while the HPV-containing oral cancer cells 686 and 1483 expressed less ICP4 (Figure 7a ).
Replication of HSPV-1
In all cells the replication of HSPV-1 was to a lower titer than that of KOS. The highest levels of HSPV-1 replication were found in Tu167 and U87 cells where titers were 34.4 and 29.6% respectively ( Table 2) . The only other cell type with HSPV-1 replication within a log of KOS replication was 1483 cells with 13.8%. 686 and U373 cells produced similar levels of infectious virus with 6.8 and 7.6%, respectively, and the brain cancer line IMR32 produced only 0.01 of the number of particles of KOS (Figure 7b) .
Cells that expressed the most ICP4 appeared to release the most virus after infection although the correlation did not reach significance at the 0.05 level (Figure 7c ). Oncolytic herpes/papillomavirus mutant C Griffith et al Inhibition of cell growth by HSPV-1 Growth of the four oral cancer cell lines was inhibited by HSPV-1 at similar levels to that of KOS at 3 days postinfection (Figure 8 ). In the brain cancer cell line U373, HSPV-1 was less inhibitory.
Effect of HSV-1 on URR16
To find if functions of HSV-1 might activate URR16, oral cancer cells were transfected with the luciferase reporter plasmid and then infected with the different strains of HSV. The infection induced expression in each of the four oral cancer cell lines (Figure 9 ) with KOS, d120 and HSPV-1. Induction by KOS was not seen when the virus had been irradiated with UV light, or fixed with formalin. KOS treated with bisulfate alone, which was used to Oncolytic herpes/papillomavirus mutant C Griffith et al neutralize the formaldehyde, showed similar induction to untreated KOS.
Discussion
Since HSV-1 infects oral epithelium naturally, it was previously proposed as an oncolytic virus for treating oral cancer. 8, 21, 22 However, wild-type HSV-1 has significant side effects when used for this purpose in animal models, with zosteriform rash, viral encephalitis and reduced survival. 5, 21 Although no strains of HSV-1 have been designed specifically for the treatment of oral cancer to date, other conditionally replicating strains have been constructed for the treatment of other cancers. One modification that has been made by others is to prevent the function of the gene for ribonucleotide reductase, thus limiting the virus to replicating cells and providing some tumor-specificity. Although this could be effective in treatment of some cancers it might be less effective in treatment of oral cancer in which the majority of cells are non-cycling. 23, 24 An alternative deletion is removal of the gene g-1-34.5, which encodes neurotoxicity. Indeed, the strain G207 which has a deletion of both ribonucleotide reductase and g-1-34.5 has shown some effectiveness in treatment of oral cancers in animals. 8 Nonetheless, all deletions appear to reduce the titer of virus significantly, which is a disadvantage. 6 An alternative to making deletions of genes is to make changes in transcriptional control of an essential gene, so that the gene is then expressed from a tumor-specific promoter. This could result in viruses that have no deletions and thus are as virulent as the wild-type virus. A suitable gene for transcriptional control is ICP4, which is essential for the replication of HSV-1. 25 Regulation of expression of ICP4 has been shown to be effective in liver cells when under the control of an albumin promoter 11 or in tumor cells when under the control of tumor-related promoters. 12, 14, 15 However, a replicating mutant is not assured by use of such constructs since in one study the CEA promoter failed to cause regulation of HSV, despite being effective in producing expression of a reporter gene. 26 There are only a small number of gene promoters that might be used to regulate the growth of a virus in an oral cancer. One is the URR from a high-risk HPV. Such viruses are found largely within squamous cell carcinomas or related conditions, and their URR is largely responsible for this specificity. 16, 17 These URRs maintain their cell-specificity when used to control expression of reporter genes in vitro 18 and are thus candidates for regulation of oncolytic viruses.
To confirm the tumor-associated activity of URR16 we selected four oral cancer cell lines and three lines of cells derived from brain cancers. The highest levels of promoter activity were seen in three of the oral cancer cell lines, while less activity was seen in the cell lines that were derived from brain tumors (Figure 2 ). Although the reason for the lower expression from Tu167 cells is unknown, it could be that these cells had a transcriptional profile more akin to undifferentiated epithelial cells, which do have a lower activity of URR16. 27, 28 The lower expression in Tu167 cells was not necessarily associated with their lack of HPV DNA ( Figure 1 ) since SCC25 cells, which also lack HPV, showed an expression level that was similar to that of the HPV-containing 1483 cells. The high level of activity in most oral cancer cells justified the incorporation of this enhancer/promoter fragment into HSV-1 for the production of an oncolytic virus.
After it had been constructed, the genome of HSPV-1 was examined to find if it met its specifications. The use of multiple PCRs, DNA sequencing and Southern blotting all confirmed that the ICP4 gene was downstream of URR16, and had been placed in the intergenic region between US9 and US10 ( Figure 3) . Others have shown that insertions may be made into this region of HSV-1 without disturbing other functions of the virus. 29 By immunoblotting it was confirmed that HSPV-1 did express the ICP4 protein, and the fact that the virus had been derived from d120 was confirmed by the additional expression of a truncated form of ICP4 ( Figure 5 ), which is known to be non-functional. 30 Quantitative immunoblotting revealed that HSPV-1 expressed ICP4 in each one of the oral cancer and brain cancer cell lines that were examined, but at levels that were less than those expressed by KOS ( Figure 6 ). In fact, the expressed level was less than 50% of that of KOS in the 686, 1483, U87 and U373 cells (Figure 7a) . The low expression in the 686 and 1483 cells was not expected, since URR16 was very active in these cells (Figure 2) . Evidently, other factors regulate the level of expression of ICP4 than just the native promoter strength of the URR. Despite this variability, the level of expression of ICP4 in HSPV-1 was sufficient to allow the virus to replicate in each of the cell types that was examined. The titers of HSPV-1 were, however, lower than those of KOS in all cell types (Figure 7b ). This included 686 and 1483 cells in which URR16 was most active (Figure 2) , and SCC25 and Tu167 cells which expressed the highest level of ICP4. In contrast, there was a discernable trend toward production of most virus from the cells that expressed the most ICP4 (Figure 7c ). The amounts of virus that were produced showed no correlation with either the level of URR16 promoter activity in cells nor with the presence of HPV sequences in their DNA.
To define the toxic effects of HSPV-1, each cell type was infected and its growth was monitored for several days. Each cell type was inhibited in growth by HSPV-1 as readily as by KOS, except for the U373 cells (Figure 8 ). This implies that the growth-inhibitory effects of herpes viruses depend on other factors than viral replication or expression of ICP4, and suggest that it is not possible to predict the effect of HSPV-1 on primary neural cells, or its likely effects in vivo.
Since the level of expression of ICP4 and the output virus titers were not completely explained by the level of promoter activity or by the presence of HPV DNA sequences in the cells, we looked for other explanations for the regulation of expression of ICP4 in HSPV-1. It seemed possible that functions of HSV-1 might be having a direct or indirect effect on activity of URR16. HSV has been reported to increase 31 or to suppress 32,33 the activities of different papillomaviruses, and cloned fragments of HSV-1 have been shown to activate the URR of HPV-16 in some cells. 34 In oral cancer cells that had been transfected with the URR-luciferase reporter plasmid, expression was increased by up to 30-fold when the cells were infected with HSV-1 ( Figure 9 ). This was seen in each of the four oral cancer cell types that were tested and with each virus. When the entry of the virus to the cell was blocked by formalin-fixation, no induction of expression was seen, indicating that the binding of the virus to the surface of the cell is not sufficient to activate expression. When the virus was previously exposed to UV light, no induction of expression was seen, indicating that expression of some genes of HSV was necessary for activation of the URR. 35 The mutant virus d120 was able to induce expression, even though the only genes that it can express are ICP0, ICP6, ICP22, ICP27 and ICP47. 36 It seems likely therefore that the induction of expression from the URR can be attributed to one or more of these five proteins. The identity of the protein and mechanism of its action, however, remain to be identified. In the URR of HPV-18 an effect of ICP0 has been localized to within a 229 bp region 37 and therefore it is possible that a small herpesresponsive portion of URR16 can be identified and deleted. This would increase the specificity of HSPV-1, and the effort to do this is now in progress.
